| Sjogren's Syndrome |
| Recruiting | 2 | 10 | | | St Vincent's Hospital / University of New South Wales, Roche Product, St Vincent's Hospital | Sjogrens Syndrome | | | | |
2016-001586-87: A Phase 2 Study of RSLV-132 in Subjects with Sjogren’s Syndrome |
|
|
| Ongoing | 2 | 28 | Europe | RSLV-132, Concentrate for solution for infusion | Resolve Therapeutics, LLC, Resolve Therapeutics, LLC | Primary Sjogrens Syndrome, Sjogrens Syndrome, Body processes [G] - Immune system processes [G12] | | | | |
NCT02679612: Safety, Pharmacokinetics and Preliminary Efficacy Study of CDZ173 in Patients With Primary Sjögren's Syndrome |
|
|
| Not yet recruiting | 2 | 27 | Europe | CDZ173, Placebo | Novartis Pharmaceuticals | Primary Sjögren's Syndrome | 12/17 | 12/17 | | |
2019-003131-31: Ravagalimab Vs Placebo in Subjects with Moderately to Severely Active Primary Sjogren's Syndrome |
|
|
| Not yet recruiting | 2 | 45 | Europe | Ravagalimab, ABBV-323, Powder for concentrate for solution for injection/infusion | AbbVie Deutschland GmbH & Co. KG, AbbVie Inc. | Moderately to Severely Active Primary Sjogren's Syndrome, An autoimmune disease affecting the entire body; symptoms include dry mouth, and serious complications such as profound fatigue, chronic pain, major organ involvement, neuropathies and lymphomas., Diseases [C] - Immune System Diseases [C20] | | | | |
| Active, not recruiting | 2 | 20 | US | Orencia, Abatacept, Placebo, Saline | Arthritis & Rheumatism Associates, P.C., Bristol-Myers Squibb | Sjogren's Syndrome | 05/21 | 12/21 | | |
2020-001933-11: Leflunomide and Hydroxychloroquine combination therapy for primary Sjögren’s Syndrome |
|
|
| Ongoing | 2 | 52 | Europe | Leflunomide, Hydroxychloroquine, Film-coated tablet, Tablet, Leflunomide, Plaquenil | University Medical Center Utrecht, ZonMw | Primary Sjogren Syndrome, Primary Sjogren Syndrome, Diseases [C] - Immune System Diseases [C20] | | | | |
2020-004937-19: A study to evaluate the safety, tolerability and efficacy of MHV370 in participants with Sjogren's Syndrome (SjS) or Mixed Connective Tissue Disease (MCTD) |
|
|
| Ongoing | 2 | 60 | Europe | MHV370, MHV370, Capsule, hard | Novartis Pharma AG, Novartis Pharma AG | Sjögren’s syndrome Mixed connective tissue disease, Sjögren’s syndrome Mixed connective tissue disease, Diseases [C] - Immune System Diseases [C20] | | | | |
2019-002470-32: Nuovi end-points clinici in pazienti con sindrome di Sjögren primaria (pSS): uno studio interventistico basato sulla stratificazione dei pazienti. NEw Clinical End-points in patients with primary Sjögren's Syndrome (pSS): an Interventional Trial based on stratifYing patients |
|
|
| Ongoing | 2 | 300 | Europe | Leflunomide, mycophenolate mofetil, Hydroxychloroquine, [Leflunomide], [mycophenolate mofetil], [Hydroxychloroquine], Tablet, Arava, Mycophenolate mofetil TEVA, PLAQUENIL | ASSITANCE PUBLIQUE DES HOPITAUX DE PARIS, Innovative Medicines Initiative 2 | Primary Sjögren's syndrome (pSS) sindrome di Sjögren primaria (pSS), Primary Sjögren's syndrome (pSS) sindrome di Sjögren primaria (pSS), Body processes [G] - Immune system processes [G12] | | | | |
2021-000665-32: A Study of Nipocalimab in Adults with Primary Sjogren's Syndrome (pSS) Un estudio de nipocalimab en adultos con síndrome de Sjögren primario (SSp) |
|
|
| Ongoing | 2 | 150 | Europe | Nipocalimab, M281, Solution for infusion | Janssen-Cilag International NV, Janssen Research & Development, LLC | Primary Sjogren's Syndrome Síndrome de Sjögren primario, Primary Sjogren's Syndrome Síndrome de Sjögren primario, Diseases [C] - Immune System Diseases [C20] | | | | |
NCT04884217: Treatment of Dry Eye Disease Using Pro-ocularâ„¢ - A Proof of Concept, Safety, and Efficacy Study |
|
|
| Enrolling by invitation | 2 | 80 | RoW | Pro-ocularâ„¢ Topical Gel, PG101, Placebo Topical Gel | PharmaDax Inc., Glia, LLC | Dry Eye Syndrome, Keratoconjunctivitis Sicca | 10/21 | 12/21 | | |
NCT04830644: A Study to Evaluate the Efficacy and Safety of Iguratimod Compared to Placebo in Patients With Active Primary Sjogren's Syndrome. |
|
|
| Recruiting | 2 | 144 | RoW | Iguratimod, Placebo | Jiangsu Simcere Pharmaceutical Co., Ltd. | Primary Sjögren Syndrome | 04/22 | 06/22 | | |
2020-005055-20: A clinical study with biopsy to investigate how ianalumab works in Sjögren`s and how safe it is Une étude clinique avec biopsie pour étudier comment l'ianalumab agit dans la maladie de Sjögren et à quel point il est sûr |
|
|
| Not yet recruiting | 2 | 24 | Europe | Ianalumab, VAY736, Solution for injection | Novartis Pharma AG, Novartis Pharma AG | Sjögren's syndrome Syndrome de Sjögren, Sjögren's syndrome Syndrome de Sjögren, Diseases [C] - Immune System Diseases [C20] | | | | |
2022-000609-28: Efficacy and safety of anifrolumab treatment for 24 weeks in patients with primary Sjögren’s syndrome compared to placebo |
|
|
| Not yet recruiting | 2 | 30 | Europe | Anifrolumab, Infusion, Saphnelo | University Medical Centre Groningen, AstraZeneca BV | Primary Sjögren's syndrome. Patients will be included if the fulfil the 2016 ACR/EULAR classification criteria for pSS and if they have active disease according to an ESSDAI score of 5 or more and/or an ESSPRI score of 5 or more., Primary Sjögren's syndrome, a systemic, auto-immune disease., Diseases [C] - Immune System Diseases [C20] | | | | |
| Completed | 2 | 183 | Europe, US, RoW | VIB4920, Dazodalibep, Placebo | Amgen | Sjögren's Syndrome | 09/22 | 03/23 | | |
| Completed | 2 | 273 | Europe, Canada, Japan, US, RoW | CFZ533, iscalimab, Placebo | Novartis Pharmaceuticals | Sjögren Syndrome | 09/22 | 06/23 | | |
| Completed | 2 | 40 | Europe | ASCs, Allogeneic adipose-derived mesenchymal stem cells, Cryostor CS10 | Rigshospitalet, Denmark | Keratoconjunctivitis Sicca, in Sjogren's Syndrome | 12/22 | 01/23 | | |
2019-002205-22: "Clinical research study to measure how good and how safe Branebrutinib compared to a placebo is in treating participants with Systemic Lupus Erythematosus or Primary Sjögren’s Syndrome, or participants with Rheumatoid Arthritis when being treated with Branebrutinib and methotrexate followed with Abatacept treatment." |
|
|
| Not yet recruiting | 2 | 185 | Europe | Branebrutinib, Abatacept, BMS-986195, BMS-188667, Capsule, hard, Solution for injection in pre-filled syringe, ORENCIA 125 mg solution for injection in pre-filled syringe | Bristol-Myers Squibb International Corporation, Bristol-Myers Squibb Research and Development, Bristol-Myers Squibb Company | SLE Sub-protocol: Systemic Lupus Erythematosus pSS Sub-protocol: Primary Sjögren’s Syndrome RA Sub-protocol: Rheumatoid Arthritis, Lupus, Sjögren’s Syndrome and Arthritis are autoimmune diseases that develops when body's immune system overreacts to unknown stimulus making antibodies/proteins directed against own's body tissues., Diseases [C] - Immune System Diseases [C20] | | | | |
2021-005911-30: A Study of the safety and effectiveness of Efgartigimod in Patients with Primary Sjögren’s Syndrome (pSS) |
|
|
| Not yet recruiting | 2 | 30 | Europe | efgartigimod, ARGX-113, Concentrate for solution for infusion | argenx BV, argenx BV | Primary Sjögren’s Syndrome, Primary Sjögren’s Syndrome, Body processes [G] - Immune system processes [G12] | | | | |
NCT05087589: Efficacy, Safety and Immunological Evaluation of Tofacitinib in the Treatment of Primary Sjogren's Syndrome |
|
|
| Recruiting | 2 | 10 | RoW | Tofacitinib | Peking University People's Hospital | Primary Sjögren's Syndrome | 01/23 | 10/23 | | |
NCT04605978: Efficacy and Safety of S95011 in Primary Sjögren's Syndrome Patients |
|
|
| Completed | 2 | 48 | Europe, US, RoW | S95011 concentrate for solution for infusion, Placebo concentrate for solution for infusion | Institut de Recherches Internationales Servier, ADIR, a Servier Group company | Primary Sjögren's Syndrome | 01/23 | 05/23 | | |
| Not yet recruiting | 2 | 30 | Europe | [89Zr]Zr-Df-crefmirlimab berdoxam, IND 127861, Solution for infusion | radboudumc, Radboudumc, Health Holland Match PPS, ReumaNederland, GSK, Galapagos | Systemic Sclerosis Sjögren's SyndromeCutaneous Lupus Erythematodus Systemische Sclerose Syndroom van SjögrenCutane Lupus Erythematodus, SclerodermaSjögren's SyndromeCLE SclerodermieSyndroom van SjögrenCLE, Diseases [C] - Immune System Diseases [C20] | | | | |
NCT04988087 / 2020-004937-19: A Study to Evaluate the Safety, Tolerability and Efficacy of MHV370 in Participants With Sjogren's Syndrome (SjS) or Mixed Connective Tissue Disease (MCTD) |
|
|
| Terminated | 2 | 30 | Europe, RoW | MHV370, Placebo | Novartis Pharmaceuticals, Novartis Pharma AG | Sjogren Syndrome, Mixed Connective Tissue Disease | 02/23 | 03/23 | | |
NCT05311514: Allogeneic Platelet Lysate Eye Drops for the Treatment of Severe Chronic Ocular Graft-versus-host Disease |
|
|
| Recruiting | 2 | 30 | RoW | Allogeneic platelet lysate eye drops | St. Petersburg State Pavlov Medical University | Ocular Graft-versus-host Disease | 04/23 | 04/24 | | |
2020-001526-59: Efficacy and safety of S95011 in primary Sjögren’s Syndrome patients |
|
|
| Not yet recruiting | 2 | 45 | Europe | S95011, S95011, Concentrate for solution for infusion | Institut de Recherches Internationales Servier, Servier Research and Development Ltd, ADIR | Primary Sjögren’s Syndrome, Primary Sjögren’s Syndrome, Diseases [C] - Immune System Diseases [C20] | | | | |
Rho plus, NCT06203457: Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren's Syndrome |
|
|
| Active, not recruiting | 2 | 24 | Europe | Efgartigimod | argenx, Iqvia Pty Ltd | Primary Sjögren's Syndrome | 02/25 | 08/25 | | |
| Completed | 2 | 163 | Europe, Japan, US, RoW | Placebo, Nipocalimab, JNJ-80202135, M281, Standard of Care Treatment | Janssen Research & Development, LLC, Janssen Research & Development, LLC | Sjogren's Syndrome | 10/23 | 11/23 | | |
| Completed | 2 | 84 | Europe, Canada, US, RoW | SAR441344, Placebo | Sanofi | Sjögren's Syndrome, Sjogren's Syndrome | 11/23 | 02/24 | | |
| Recruiting | 2 | 300 | Europe | Hydroxychloroquine 400mg/d, Leflunomide 20mg/d, Mycophenolate mofetil 2000mg/d, Placebo of Hydroxychloroquine 400mg/d, Placebo of Leflunomide 20mg/d, Placebo of Mycophenolate mofetil 2000mg/d | Assistance Publique - Hôpitaux de Paris | Primary Sjögren's Syndrome (pSS) | 02/24 | 04/25 | | |
rho, NCT05817669: A Study of the Safety and Effectiveness of Efgartigimod in Patients With Primary Sjögren's Syndrome (pSS) |
|
|
| Completed | 2 | 34 | Europe | Efgartigimod, Placebo | argenx, Iqvia Pty Ltd | Primary Sjögren's Syndrome | 01/24 | 02/24 | | |
| Recruiting | 2 | 30 | Europe | Anifrolumab, Saphnelo, Placebo | University Medical Center Groningen, AstraZeneca | Sjogren's Syndrome | 05/24 | 08/24 | | |
NCT06381986: Efficacy and Safety of SHJ002 Ophthalmic Solution in the Treatment of Corneal Erosion in Sjogren's Patients |
|
|
| Not yet recruiting | 2 | 122 | RoW | SHJ002, Vehicle | Sunhawk Vision Biotech, Inc. | Corneal Erosion | 01/25 | 02/25 | | |
| Active, not recruiting | 2 | 206 | Europe, Canada, Japan, US, RoW | CFZ533 (iscalimab), iscalimab, CFZ533 Placebo, Placebo | Novartis Pharmaceuticals | Sjogren's Syndrome | 07/24 | 07/24 | | |
NCT06312020: A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome |
|
|
| Recruiting | 2 | 262 | US | HZN-1116, VIB1116, Placebo | Amgen | Sjogren's Syndrome | 09/26 | 12/26 | | |
NCT05016297: Efficacy and Safety of Baricitinib in Sjogren's Syndrome |
|
|
| Active, not recruiting | 2 | 90 | RoW | Baricitinib, Hydroxychloroquine | Peking Union Medical College Hospital, Eli Lilly and Company | Sjogren's Syndrome | 08/24 | 11/24 | | |
| Recruiting | 2 | 15 | US | Levocarnitine, Placebo | Vanderbilt University Medical Center | Sjogren's Syndrome, Keratoconjunctivitis Sicca | 03/25 | 03/25 | | |
NCT06440525: A Phase 2 Study of RSLV-132 in Females With Primary Sjögren's Syndrome |
|
|
| Not yet recruiting | 2 | 106 | NA | RSLV-132, Placebo | Resolve Therapeutics | Primary Sjögren Syndrome | 05/26 | 07/26 | | |
NCT05781451: Anti-BTLA Agonist Therapy in Subjects With Primary Sjogren's Syndrome |
|
|
| Withdrawn | 2 | 12 | NA | LY3361237, Venanprubart | Stanford University | Primary Sjogren's Syndrome | 01/27 | 01/28 | | |
NCT05124925: Biopsy Based Study to Understand Mechanism of Action of Ianalumab in Salivary Glands and Explore Relationships With Clinical Assessments. |
|
|
| Active, not recruiting | 2 | 21 | Europe | Ianalumab | Novartis Pharmaceuticals | Sjogren Syndrome | 06/26 | 06/26 | | |
NCT05605665: Low-dose Interleukin-2 and Rapamycin on sjögren's Syndrome |
|
|
| Recruiting | 1/2 | 30 | RoW | low-dose interleukin-2, Recombinant Human Interleukin-2, rapamycin, sirolimus | Peking University People's Hospital | Sjögren's Syndrome | 11/23 | 12/23 | | |
NCT06049368: 68Ga-P16-093 PET/CT Imaging in the Salivary Gland |
|
|
| Not yet recruiting | 1/2 | 40 | NA | 68Ga-P16-093 | Peking Union Medical College Hospital | Primary Sjögren Syndrome | 12/23 | 03/24 | | |
BAH247, NCT06428188: Sequential CAR-T Cells Targeting BCMA/CD19 in Patients With Relapsed/ Refractory Autoimmune Diseases |
|
|
| Recruiting | 1/2 | 60 | RoW | BCMA/CD19 CAR-T cells | Essen Biotech | Autoimmune Diseases, Systemic Lupus Erythematosus, Systemic Lupus Erythematosus Acute, Sjogren's Syndrome | 12/25 | 12/26 | | |
BAH242, NCT06350110: Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE) |
|
|
| Not yet recruiting | 1/2 | 75 | RoW | CD19- BCMA CAR-T cells, EB-BH2024-2 | Essen Biotech | Systemic Lupus Erythematosus, Lupus Nephritis, Autoimmune Diseases, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Granulomatous Polyangiitis, Microscopic Polyangiitis, Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Sjogren's Syndrome | 12/25 | 12/25 | | |
NCT04496960: Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's Syndrome |
|
|
| Recruiting | 1/2 | 76 | US | tofacitinib, Placebo | National Institute of Dental and Craniofacial Research (NIDCR) | Sjogren's Syndrome | 09/25 | 09/25 | | |
